Cancer diagnostics market seen reaching $343.3 billion by 2033

The global cancer diagnostics market is projected to rise from $185.4 billion in 2026 to $343.3 billion by 2033, driven by early detection, precision medicine and broader screening programs. North America leads the market now, while Asia Pacific is positioned for faster expansion as healthcare access and lab infrastructure improve.

Why it matters: - Cancer diagnostics is becoming a core part of oncology care as providers push earlier detection, more precise treatment decisions and better patient outcomes. - The market outlook points to sustained demand for imaging, molecular diagnostics, pathology, biomarker testing and liquid biopsy. - Growth in screening programs and healthcare infrastructure is expanding access to advanced testing.

What happened: - Persistence Market Research projected the global cancer diagnostics market will grow from US$185.4 billion in 2026 to US$343.3 billion by 2033. - The forecast implies a 9.2% compound annual growth rate from 2026 to 2033. - The report said molecular diagnostics is a leading segment and hospitals remain the top end users. - North America holds the largest regional share because of advanced healthcare infrastructure, high healthcare spending, reimbursement support and fast adoption of new diagnostic tools. - The report was published July 20, 2026. - The full sample report is available here.

The details: - The market is segmented by product type, technology, cancer type, application and end user. - Product categories include imaging systems, molecular diagnostics, pathology, biopsy devices, laboratory testing solutions and companion diagnostics. - Molecular diagnostics is gaining share because it supports genetic profiling and personalized treatment selection. - Imaging technologies remain important for detection, staging and treatment monitoring. - End users include hospitals, diagnostic laboratories, specialty clinics, research institutes and academic medical centers. - Hospitals lead because they combine oncology services with advanced diagnostic equipment. - Diagnostic laboratories are expanding as demand rises for specialized testing. - Research organizations are contributing through biomarker discovery and new diagnostic technologies. - AI integration is improving diagnostic accuracy and workflow efficiency. - The company offers customization of the report. - The full report can be purchased here.

Between the lines: - The market thesis is shifting toward precision oncology, where diagnostics guide therapy instead of only confirming disease. - AI and digital pathology are emerging as force multipliers because they can speed interpretation and reduce reporting time. - High equipment costs, skilled labor needs and regulatory delays still limit adoption, especially in developing economies. - Reimbursement gaps, data privacy concerns and integration issues with digital platforms remain barriers to broader rollout. - Emerging economies could become the next growth engine as screening awareness and healthcare spending rise.

What's next: - Demand should continue to rise as cancer prevalence grows and more health systems prioritize screening and early diagnosis. - Biomarker testing, genomic sequencing, companion diagnostics and liquid biopsy are expected to see sustained uptake. - North America is expected to stay the largest market, while Asia Pacific is projected to post substantial growth on the back of healthcare modernization and laboratory expansion. - Key companies in the space include Abbott Laboratories, F. Hoffmann-La Roche, Thermo Fisher Scientific, Siemens Healthineers, Danaher, QIAGEN, Agilent, Illumina, Bio-Rad, Becton Dickinson, GE HealthCare, Philips, Hologic, Sysmex and Canon Medical Systems.